EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy

Chengxiang Wu iD, Nathan M Johnson, Shan Yu iD, Agnes S Lo, Gautam K Sahu, Preston A Marx, Dorothee von Laer, Gail Skowron, Romas Geleziunas, George M Shaw iD, Amitinder Kaur, Richard P Junghans und 1 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.01933-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Chengxiang Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Cytomegalovirus, HIV Infections, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of chimeric antigen receptor (CAR)-T cell (Tc) immunotherapy in refractory B-cell acute lymphoblastic leukemia (B-ALL) suggests adaptation of this strategy toward HIV. Because cytomegalovirus (CMV) vaccine vectors generated Tc responses that controlled viral replication, these studies aim to genetically modify CMV-specific Tc with HIV-CAR2 vectors and link HIV immunotherapy to persistent CMV antigen stimulation. To mimic a clinical scenario, rhesus macaques were challenged with the CCR5-tropic simian/human immunodeficiency virus (SHIV-D) prior to antiretroviral therapy (ART). Autologous CMV-specific Tc were transduced with the control CEA-CAR2 or CD4-CAR2/maC46 vectors and reinfused. After stopping ART, the plasma viral load (PVL) in the control rebounded and was sustained above 1.7 × 10 4 copies/mL; PVL in CD4-CAR2-treated animals was delayed up to 6 weeks and 10-fold lower. The CD4 CAR-Tc frequency peaked at day 7 and was detected in lymphoid tissues at 6 weeks. Both CEA-CAR2 and CD4-CAR2 persisted in PBMCs for about 2 years, which indicates that the CMV-specific CAR Tc were maintained based on their CMV specificity. However, long-term PVL was stable in all animals. Thus, CMV-specific CAR-Tc were active initially, persisted long term, but failed to control viral replication. IMPORTANCE Because of latent viral reservoirs and a dysfunctional immune response, HIV replication rebounds when antiretroviral therapy is interrupted. Therefore, cytomegalovirus (CMV)-specific Tc were genetically modified with anti-HIV CD4-CAR2 vectors to link the targeting of the HIV envelope to the persistent CMV immune response. In this clinical scenario with simian/human immunodeficiency virus (SHIV) challenge and antiretroviral therapy (ART) suppression, early activity of the CAR Tc delayed rebound in the rhesus macaque/SHIV challenge model. However, even with long-term persistence of CAR Tc in the blood, control of viral replication was not achieved. These data suggest that CAR Tc will require additional interventions to cure HIV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCytomegalovirusHIV InfectionsReceptors, Chimeric AntigenT-LymphocytesAnimalsMacaca mulattaViral LoadHumansSimian Immunodeficiency VirusVirus ReplicationHIV-1CD4-Positive T-LymphocytesSimian Acquired Immunodeficiency Syndrome

Stichwörter der Autor:innen

CD4-CAR T cellsCMV-specific immune responsesadoptive immunotherapypersistence and biodistributionrhesus SHIV-challenge model

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
  • Department of Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Tufts Medical School, Boston, Massachusetts, USA.
  • Roger Williams Medical Center, Providence, Rhode Island, USA.
  • Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Medizinische Universität Innsbruck, Innsbruck, Austria.

ORCID-Profile: Chengxiang Wu, Shan Yu, George M Shaw, Stephen E Braun

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NHLBI NIH HHS
  • NIH HHS
  • Tulane University School of Medicine
  • NCRR NIH HHS
  • National Center for Research Resources

Zitieren

APA

Wu, C., Johnson, N. M., Yu, S., Lo, A. S., Sahu, G. K., Marx, P. A., von Laer, D., Skowron, G., Geleziunas, R., Shaw, G. M., Kaur, A., Junghans, R. P., & Braun, S. E. (2025). Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy. Journal of Virology. https://doi.org/10.1128/jvi.01933-24

Vancouver

Wu C, Johnson NM, Yu S, Lo AS, Sahu GK, Marx PA, et al. Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy. Journal of Virology. 2025. doi:10.1128/jvi.01933-24

BibTeX
@article{Wu2025,
  author = {Wu, Chengxiang and Johnson, Nathan M and Yu, Shan and Lo, Agnes S and Sahu, Gautam K and Marx, Preston A and von Laer, Dorothee and Skowron, Gail and Geleziunas, Romas and Shaw, George M and Kaur, Amitinder and Junghans, Richard P and Braun, Stephen E},
  title = {Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01933-24}
}
Kostenlos starten →